Financial Performance - Consolidated revenues increased 43% year-over-year to $64.3 million, with telehealth revenue up 60% to $49.9 million[6] - Adjusted EBITDA increased 78% to $9.0 million, while telehealth adjusted EBITDA surged 396% to $5.9 million[6] - Total revenues for the year ended December 31, 2024, were $212.45 million, up from $152.55 million in 2023, representing a 39.2% growth[21] - Gross profit for Q4 2024 was $54.82 million, compared to $39.50 million in Q4 2023, indicating a 38.8% increase[21] - Operating income for Q4 2024 was $1.02 million, a significant improvement from an operating loss of $2.17 million in Q4 2023[21] - For the fourth quarter ended December 31, 2024, the consolidated adjusted EBITDA was $8,981,997, compared to $5,048,167 for the same period in 2023, representing a 77.4% increase[30] - The adjusted EPS for the fourth quarter of 2024 was $0.21, up from $0.14 in the fourth quarter of 2023, reflecting a 50% increase[31] Subscriber Growth - Telehealth active subscribers rose 27% to approximately 275,000 at quarter-end[7] Cash Flow and Liquidity - Full-year cash flow from operations increased 99% to $17.5 million, generating positive full-year net cash flow[6] - The company exited 2024 with over $35 million in cash[6] - Cash at the end of Q4 2024 was $35.00 million, compared to $33.15 million at the end of Q4 2023[23] Future Guidance - For 2025, the company introduced guidance for consolidated revenue of $265 million to $275 million and consolidated adjusted EBITDA of $30 million to $32 million[4] Expenses and Losses - Total expenses for the year ended December 31, 2024, were $204.53 million, up from $148.14 million in 2023, reflecting a 38.0% increase[21] - GAAP net loss was $0.9 million or $0.02 per share, an improvement from a loss of $4.5 million or $0.12 per share in the previous year[10] - Net loss attributable to LifeMD, Inc. common stockholders for Q4 2024 was $0.88 million, an improvement from a loss of $4.51 million in Q4 2023[21] - The net loss attributable to common shareholders for the year ended December 31, 2024, was $(21,987,982), a decrease from $(23,702,242) in 2023, indicating an improvement of 7.2%[30] Operational Developments - WorkSimpli business returned to growth with adjusted EBITDA exceeding $1 million per month during the quarter[4] - The company plans to launch a virtual-first behavioral health offering and a women's health specialty offering later this year[4] Telehealth Performance - Telehealth revenue for Q4 2024 reached $49.89 million, a 59.5% increase from $31.26 million in Q4 2023[21] - Telehealth adjusted EBITDA for the fourth quarter of 2024 was $5,870,484, compared to $1,183,037 in the same quarter of 2023, marking a significant increase of 396.5%[32] - The company reported a telehealth operating loss of $(92,328) for Q4 2024, a significant improvement from $(4,401,440) in Q4 2023[32] Other Financial Metrics - Gross margin was 85% compared to 88% due to one-time start-up costs, with expectations to return to 88%-90% in 2025[10] - Stock-based compensation expense for the year ended December 31, 2024, was $12,234,797, slightly down from $12,489,343 in 2023, a decrease of 2.0%[30] - Interest expense (excluding amortization of debt discount) for the year ended December 31, 2024, was $1,780,042, compared to $1,755,656 in 2023, an increase of 1.4%[30] - The company incurred litigation costs of $376,030 in Q4 2024, compared to $168,600 in Q4 2023, representing an increase of 123.5%[30] - The total dividends paid for the year ended December 31, 2024, were $3,106,250, down from $5,227,450 in 2023, a decrease of 40.5%[30]

Core Insights - LifeMD, Inc. is integrating with LillyDirect pharmacy provider Gifthealth to enhance access to Lilly's obesity treatment Zepbound for eligible patients [1][2] - The integration aims to provide a seamless fulfillment process for Zepbound, which is now available at reduced prices through the self-pay pharmacy channel [3][4] - LifeMD's weight management program has grown to approximately 75,000 active patient subscribers as of February 2025, positioning the company as a leader in the weight-loss market [3] Company Overview - LifeMD is a leading provider of virtual primary care, offering telemedicine, laboratory and pharmacy services, and specialized treatment across over 200 conditions [5] - The company utilizes a vertically integrated digital care platform and has a 50-state affiliated medical group, enhancing access to affordable healthcare [5] Product Details - Zepbound is the first FDA-approved dual GLP-1 receptor agonist and GIP obesity medication, available in 2.5 mg, 5 mg, 7.5 mg, and 10 mg doses through LillyDirect [2][4] - Recent price reductions for the 2.5 mg and 5 mg vials, along with the launch of new doses, aim to make the treatment more accessible [4]

Company Overview - LifeMD, Inc. is a leading provider of virtual primary care services, offering telemedicine, laboratory and pharmacy access, and specialized treatment for over 200 conditions [2] - The company utilizes a vertically integrated digital care platform, a 50-state affiliated medical group, a 22,500-square-foot affiliated pharmacy, and a U.S.-based patient care center to enhance access to high-quality and affordable care [2] Recent Developments - LifeMD announced its participation in the KeyBanc Capital Markets Healthcare Forum, scheduled for March 18-19, 2025, where management will engage in a fireside chat and hold one-on-one meetings [1]

Core Viewpoint - LifeMD, Inc. is set to report its financial results for the year ending December 31, 2024, on March 10, 2025, after U.S. market close, followed by a conference call to discuss the results [1] Company Overview - LifeMD, Inc. is a prominent provider of virtual primary care services, offering telemedicine, laboratory and pharmacy access, and specialized treatment for over 200 conditions, including primary care, men's and women's health, weight management, and hormone therapy [2] - The company utilizes a vertically integrated, proprietary digital care platform, supported by a 50-state affiliated medical group, a 22,500-square-foot affiliated pharmacy, and a U.S.-based patient care center to enhance access to high-quality and affordable care [2]

Core Viewpoint - LifeMD, Inc. is expanding its services to include behavioral health offerings such as teletherapy, psychiatry, and medication management, led by industry veteran Julian Cohen [1][2][3] Company Overview - LifeMD is a leading provider of virtual primary care services, offering telemedicine and specialized treatment across more than 200 conditions [8] - The company utilizes a vertically integrated digital care platform and has a 50-state affiliated medical group [8] Leadership and Expertise - Julian Cohen has over 30 years of experience in the medical and behavioral health industries and will oversee clinical operations for LifeMD's new services [2][4] - Cohen's previous roles include Chief Clinical Services Officer at UpLift and Senior Vice President of Behavioral Health at Hims, where he successfully launched mental health programs [4][5] Market Need and Strategy - Approximately 59.3 million U.S. adults were living with a mental illness in 2022, with only 50.6% receiving treatment, indicating a significant market need for accessible mental health services [3] - LifeMD aims to improve access to behavioral healthcare by expanding insurance coverage across commercial and government payers [3][4] Service Expansion - The new behavioral health services will integrate psychotherapy and psychiatry into LifeMD's holistic care approach, addressing common mental health conditions [3][4] - The expansion is seen as timely due to the growing demand for affordable and accessible behavioral healthcare [4]

Company Overview - LifeMD, Inc. is a leading provider of virtual primary care services, offering telemedicine, laboratory and pharmacy access, and specialized treatment for over 200 conditions [2] - The company operates a vertically integrated digital care platform, a 50-state affiliated medical group, and a 22,500-square-foot affiliated pharmacy [2] - LifeMD aims to increase access to high-quality and affordable care through its U.S.-based patient care center [2] Recent Developments - LifeMD announced its participation in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference scheduled for February 11-12, 2025 [1] - Management will engage in one-on-one meetings throughout the conference to discuss the company's initiatives and growth strategies [1]

LifeMD: Investor Presentation November 2024 NASDAQ: LFMD 9:41 .. Il 令 ■ = Schedule your appointment Today Tomorrow ASAP Jan 23 Jan 24 -20 min wait Dr. Jennell Giles of Any available provider + Schedule an appointment Possible conditions: Middle ear infection Strong evidence Inflamation of external ear 2 Important cautions regarding forward-looking statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the S ...

Financial Data and Key Metrics Changes - LifeMD achieved total revenues of $53.4 million for Q3 2024, representing a 38% increase year-over-year [29] - Core telehealth revenue grew by 65% compared to the prior year, with adjusted EBITDA profitability at $2.5 million, up 200% sequentially [30][31] - Consolidated gross margin reached a record 90.6%, up 300 basis points year-over-year, with gross profit increasing by 43% [32] - GAAP net loss attributable to common stockholders was $5.9 million, an improvement from a loss of $6.9 million in Q3 2023 [33] - Adjusted EBITDA totaled $3.7 million for Q3, compared to $2.8 million in the same period last year [34] Business Line Data and Key Metrics Changes - Telehealth subscriber growth remained strong, with active subscribers increasing by 30% year-over-year to approximately 269,000 [31] - Weight management subscribers increased by 15,000 during the quarter, bringing the total to about 75,000 [71] - WorkSimpli's active subscribers contracted by 6% but returned to sequential growth, reflecting a turning point in performance [31][28] Market Data and Key Metrics Changes - LifeMD's telehealth business represented more than 75% of total revenue in Q3, up from 63% a year ago [28] - The company is expanding its pharmacy capabilities, with a new facility expected to be accretive in 2025 [9][10] Company Strategy and Development Direction - LifeMD is focused on expanding clinical offerings, differentiating weight management services, and accelerating growth in the men's health business [8] - The company aims to launch Medicare services in the first half of 2025, targeting a significant market opportunity [13] - LifeMD is enhancing its weight management model with new treatment options and AI-driven technology [22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the long-term potential of the telehealth business, emphasizing the scalability and resilience of their model [40] - The company is well-positioned to redefine virtual care with new AI-driven tools and expanded insurance capabilities [43] - Management highlighted the importance of improving access to GLP-1 medications and the anticipated agreements with payers [49][50] Other Important Information - LifeMD generated over $6.2 million in cash flow from operations during Q3 2024 and has maintained positive net cash flow for four consecutive quarters [36] - The company is reiterating its guidance for 2024 total revenues of at least $205 million, raising telehealth revenue guidance to between $151 million and $152 million [37] Q&A Session Summary Question: Can you talk about the FDA's comments on semaglutide and tirzepatide? - Management indicated that compounded GLP-1 medications are unlikely to be prohibited by the FDA and emphasized the importance of access to branded therapies [46][48] Question: Can you explain the strong telehealth margins in Q3? - Management attributed the strong margins to improved retention, upselling longer subscriptions, and a higher percentage of service revenue [59][61] Question: How many weight management subscribers were added in the quarter? - The company added 15,000 net new weight management subscribers, increasing the total to approximately 75,000 [71] Question: What are the key differentiators for LifeMD's weight management offering? - Management highlighted the quality of care and comprehensive virtual primary care services as key differentiators [80][82] Question: What are the growth drivers for 2025? - Management expects GLP-1 therapies and the men's telehealth business to be significant growth drivers, along with new offerings in behavioral health and chronic condition management [85][88]

Company Performance - LifeMD, Inc. reported a quarterly loss of $0.14 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.10, representing an earnings surprise of -40% [1] - The company posted revenues of $53.39 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 0.26%, but showing an increase from $38.61 million in the same quarter last year [2] - Over the last four quarters, LifeMD has surpassed consensus EPS estimates only once, while it has topped consensus revenue estimates three times [2] Stock Performance - LifeMD shares have declined approximately 39% since the beginning of the year, contrasting with the S&P 500's gain of 24.3% [3] - The current Zacks Rank for LifeMD is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $57.63 million, and for the current fiscal year, it is -$0.49 on revenues of $205.5 million [7] - The trend of estimate revisions for LifeMD is mixed, which could change following the recent earnings report [6] Industry Context - The Medical Services industry, to which LifeMD belongs, is currently ranked in the bottom 45% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - The performance of LifeMD may also be influenced by the overall outlook for the industry [8]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 76-0238453 (State or other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) Title of each class Trading symbol(s) Name of exchange on which registered Common Stock, par value $.01 per share LFMD The Nasdaq Global Market 8.875% Series A Cumulative Perpetual Preferred Stock, par value $0.0001 per share LFMDP The Nasdaq Global Market Large accelerated filer ☐ Accelerated filer ☒ Non-accelerated f ...